New treatment options for gliomas

被引:0
作者
Wick, Wolfgang [1 ,2 ,3 ]
机构
[1] Heidelberg Univ, Neurol Klin, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Natl Zentrum Tumorerkrankungen Heidelberg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
[3] German Canc Res Ctr, German Canc Consortium DKTK, Clin Cooperat Unit CCU Neurooncol, Heidelberg, Germany
来源
ONKOLOGE | 2019年 / 25卷 / 01期
关键词
Brain tumors; Immunotherapy; Precision medicine; IDH mutations; EGFRv3; expression; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT GLIOBLASTOMA; PHASE-II; TEMOZOLOMIDE; RADIOTHERAPY; BEVACIZUMAB; MONOTHERAPY; SURVIVAL; EFFICACY; SAFETY;
D O I
10.1007/s00761-018-0479-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundPatients with gliomas in molecularly defined subgroups (isocitrate dehydrogenase, IDH mutation, 1p/19q codeletion) already benefit now from standard treatments. The O6-methylguanine DNA-methyltransferase (MGMT) is the only relevant biomarker for treatment decisions for or against alkylating chemotherapy.PurposeIn the present review article new concepts of immunotherapy and targeted approaches as well as treatment with electrical fields for gliomas are discussed.ResultsIn recent years there have been efforts to develop study concepts with molecular targeted treatment for patients with gliomas harboring IDH mutations, endothelial growth factor receptor (EGFR) overexpression, EGFRv3 expression and also other defined molecular alterations in tumor tissue. Current treatment studies transfer these to studies involving single biomarkers in so-called modern umbrella designs. In these umbrella concepts asingle disease entity is treated in different study groups with molecular targeted treatments based on molecular biomarker tests. Key outcomes of these trials are not only patients who benefit but also information on sensitivity or resistance mechanisms of the examined treatments. Similar trials are being designed for immunotherapies with variable approaches involving checkpoint inhibition on the one side and different vaccination approaches including the use of chimeric antigen receptor (CAR) cells on the other.ConclusionAlternating electrical fields are atherapeutic option available for patients with newly diagnosed glioblastoma after successful completion of chemoradiation.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 32 条
  • [1] Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
    Alexander, Brian M.
    Ba, Sujuan
    Berger, Mitchel S.
    Berry, Donald A.
    Cavenee, Webster K.
    Chang, Susan M.
    Cloughesy, Timothy F.
    Jiang, Tao
    Khasraw, Mustafa
    Li, Wenbin
    Mittman, Robert
    Poste, George H.
    Wen, Patrick Y.
    Yung, W. K. Alfred
    Barker, Anna D.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (04) : 737 - 743
  • [2] A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
    Brandes, Alba A.
    Carpentier, Antoine F.
    Kesari, Santosh
    Sepulveda-Sanchez, Juan M.
    Wheeler, Helen R.
    Chinot, Olivier
    Cher, Lawrence
    Steinbach, Joachim P.
    Capper, David
    Specenier, Pol
    Rodon, Jordi
    Cleverly, Ann
    Smith, Claire
    Gueorguieva, Ivelina
    Miles, Colin
    Guba, Susan C.
    Desaiah, Durisala
    Lahn, Michael M.
    Wick, Wolfgang
    [J]. NEURO-ONCOLOGY, 2016, 18 (08) : 1146 - 1156
  • [3] DNA methylation-based classification of central nervous system tumours
    Capper, David
    Jones, David T. W.
    Sill, Martin
    Hovestadt, Volker
    Schrimpf, Daniel
    Sturm, Dominik
    Koelsche, Christian
    Sahm, Felix
    Chavez, Lukas
    Reuss, David E.
    Kratz, Annekathrin
    Wefers, Annika K.
    Huang, Kristin
    Pajtler, Kristian W.
    Schweizer, Leonille
    Stichel, Damian
    Olar, Adriana
    Engel, Nils W.
    Lindenberg, Kerstin
    Harter, Patrick N.
    Braczynski, Anne K.
    Plate, Karl H.
    Dohmen, Hildegard
    Garvalov, Boyan K.
    Coras, Roland
    Hoelsken, Annett
    Hewer, Ekkehard
    Bewerunge-Hudler, Melanie
    Schick, Matthias
    Fischer, Roger
    Beschorner, Rudi
    Schittenhelm, Jens
    Staszewski, Ori
    Wani, Khalida
    Varlet, Pascale
    Pages, Melanie
    Temming, Petra
    Lohmann, Dietmar
    Selt, Florian
    Witt, Hendrik
    Milde, Till
    Witt, Olaf
    Aronica, Eleonora
    Giangaspero, Felice
    Rushing, Elisabeth
    Scheurlen, Wolfram
    Geisenberger, Christoph
    Rodriguez, Fausto J.
    Becker, Albert
    Preusser, Matthias
    [J]. NATURE, 2018, 555 (7697) : 469 - +
  • [4] Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
    Capper, David
    von Deimling, Andreas
    Brandes, Alba A.
    Carpentier, Antoine F.
    Kesari, Santosh
    Sepulveda-Sanchez, Juan M.
    Wheeler, Helen R.
    Chinot, Olivier
    Cher, Lawrence
    Steinbach, Joachim P.
    Specenier, Pol
    Rodon, Jordi
    Cleverly, Ann
    Smith, Claire
    Gueorguieva, Ivelina
    Miles, Colin
    Guba, Susan C.
    Desaiah, Durisala
    Estrem, Shawn T.
    Lahn, Michael M.
    Wick, Wolfgang
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [5] Comprehensive genomic characterization defines human glioblastoma genes and core pathways
    Chin, L.
    Meyerson, M.
    Aldape, K.
    Bigner, D.
    Mikkelsen, T.
    VandenBerg, S.
    Kahn, A.
    Penny, R.
    Ferguson, M. L.
    Gerhard, D. S.
    Getz, G.
    Brennan, C.
    Taylor, B. S.
    Winckler, W.
    Park, P.
    Ladanyi, M.
    Hoadley, K. A.
    Verhaak, R. G. W.
    Hayes, D. N.
    Spellman, Paul T.
    Absher, D.
    Weir, B. A.
    Ding, L.
    Wheeler, D.
    Lawrence, M. S.
    Cibulskis, K.
    Mardis, E.
    Zhang, Jinghui
    Wilson, R. K.
    Donehower, L.
    Wheeler, D. A.
    Purdom, E.
    Wallis, J.
    Laird, P. W.
    Herman, J. G.
    Schuebel, K. E.
    Weisenberger, D. J.
    Baylin, S. B.
    Schultz, N.
    Yao, Jun
    Wiedemeyer, R.
    Weinstein, J.
    Sander, C.
    Gibbs, R. A.
    Gray, J.
    Kucherlapati, R.
    Lander, E. S.
    Myers, R. M.
    Perou, C. M.
    McLendon, Roger
    [J]. NATURE, 2008, 455 (7216) : 1061 - 1068
  • [6] Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
    Cloughesy, Timothy F.
    Landolfi, Joseph
    Hogan, Daniel J.
    Bloomfield, Stephen
    Carter, Bob
    Chen, Clark C.
    Elder, J. Bradley
    Kalkanis, Steven N.
    Kesari, Santosh
    Lai, Albert
    Lee, Ian Y.
    Liau, Linda M.
    Mikkelsen, Tom
    Nghiemphu, Phioanh Leia
    Piccioni, David
    Walbert, Tobias
    Chu, Alice
    Das, Asha
    Diago, Oscar R.
    Gammon, Dawn
    Gruber, Harry E.
    Hanna, Michelle
    Jolly, Douglas J.
    Kasahara, Noriyuki
    McCarthy, David
    Mitchell, Leah
    Ostertag, Derek
    Robbins, Joan M.
    Rodriguez-Aguirre, Maria
    Vogelbaum, Michael A.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (341)
  • [7] Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
    Geletneky, Karsten
    Hajda, Jacek
    Angelova, Assia L.
    Leuchs, Barbara
    Capper, David
    Bartsch, Andreas J.
    Neumann, Jan-Oliver
    Schoening, Tilman
    Huesing, Johannes
    Beelte, Birgit
    Kiprianova, Irina
    Roscher, Mandy
    Bhat, Rauf
    von Deimling, Andreas
    Brueck, Wolfgang
    Just, Alexandra
    Frehtman, Veronika
    Loebhard, Stephanie
    Terletskaia-Ladwig, Elena
    Fry, Jeremy
    Jochims, Karin
    Daniel, Volker
    Krebs, Ottheinz
    Dahm, Michael
    Huber, Bernard
    Unterberg, Andreas
    Rommelaere, Jean
    [J]. MOLECULAR THERAPY, 2017, 25 (12) : 2620 - 2634
  • [8] Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
    Kessler, Tobias
    Sahm, Felix
    Sadik, Ahmed
    Stichel, Damian
    Hertenstein, Anne
    Reifenberger, Guido
    Zacher, Angela
    Sabel, Michael
    Tabatabai, Ghazaleh
    Steinbach, Joachim
    Sure, Ulrich
    Krex, Dietmar
    Grosu, Anca-L
    Bewerunge-Hudler, Melanie
    Jones, David
    Pfister, Stefan M.
    Weller, Michael
    Opitz, Christiane
    Bendszus, Martin
    von Deimling, Andreas
    Platten, Michael
    Wick, Wolfgang
    [J]. NEURO-ONCOLOGY, 2018, 20 (03) : 367 - 379
  • [9] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
    Liau, Linda M.
    Ashkan, Keyoumars
    Tran, David D.
    Campian, Jian L.
    Trusheim, John E.
    Cobbs, Charles S.
    Heth, Jason A.
    Salacz, Michael
    Taylor, Sarah
    D'andre, Stacy D.
    Iwamoto, Fabio M.
    Dropcho, Edward J.
    Moshel, Yaron A.
    Walter, Kevin A.
    Pillainayagam, Clement P.
    Aiken, Robert
    Chaudhary, Rekha
    Goldlust, Samuel A.
    Bota, Daniela A.
    Duic, Paul
    Grewal, Jai
    Elinzano, Heinrich
    Toms, Steven A.
    Lillehei, Kevin O.
    Mikkelsen, Tom
    Walpert, Tobias
    Abram, Steven R.
    Brenner, Andrew J.
    Brem, Steven
    Ewend, Matthew G.
    Khagi, Simon
    Portnow, Jana
    Kim, Lyndon J.
    Loudon, William G.
    Thompson, Reid C.
    Avigan, David E.
    Fink, Karen L.
    Geofroy, Francois J.
    Lindhorst, Scott
    Lutzky, Jose
    Sloan, Andrew E.
    Schackert, Gabriele
    Krex, Dietmar
    Meisel, Hans-Jorg
    Wu, Julian
    Davis, Raphael P.
    Duma, Christopher
    Etame, Arnold B.
    Mathieu, David
    Kesari, Santosh
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16 : 1
  • [10] Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research
    Madhavan, Subha
    Zenklusen, Jean-Claude
    Kotliarov, Yuri
    Sahni, Himanso
    Fine, Howard A.
    Buetow, Kenneth
    [J]. MOLECULAR CANCER RESEARCH, 2009, 7 (02) : 157 - 167